| Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. | |
| | |
MedLine Citation:
|
PMID: 20848399 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Cumulative evidence implicates the epidermal growth factor receptor (EGFR) as an important therapeutic target in head and neck squamous cell carcinoma (HNSCC). The basis for the lack of correlation between EGFR expression in the HNSCC tumor and clinical responses to EGFR inhibitors is incompletely understood. Although a variety of mechanisms likely contribute to the effectiveness of EGFR blockade, this review focuses on the biologic implications of known EGFR variations and the role of the immune system in mediating clinical responses to EGFR inhibitors. METHODS: A Medline review of articles published in the last 10 years (1999-present) on EGFR in HNSCC was performed in combination with preliminary data from our laboratories. RESULTS: Studies published to date suggest no association between the expression of EGFR on HNSCC tumors and clinical responses to EGFR inhibitors. Several mechanisms have been proposed to mediate clinical response to EGFR inhibitors in HNSCC. Cumulative results from our laboratories support the role of several mechanisms, including cellular immune activation and mutated EGFR variants, in contributing to the discrepancy between level of EGFR expression and clinical response to EGFR inhibitors. CONCLUSION: The efficacy of EGFR targeted therapies may be mediated, at least in part, by the immune system and the presence of the truncated EGFR variant, EGFRvIII, among other factors. Criteria to identify the subset of patients likely to be responsive to EGFR targeted therapies are needed. |
| | |
Authors:
|
Mark E Sharafinski; Robert L Ferris; Soldano Ferrone; Jennifer R Grandis |
Related Documents
:
|
19887199 - Effects of pterostilbene on melanoma alone and in synergy with inositol hexaphosphate. 12543719 - Placental growth factor (plgf) and its receptor flt-1 (vegfr-1): novel therapeutic targ... 3726549 - A macrophage-derived factor required by plasmacytomas for survival and proliferation in... 12801979 - Bone morphogenetic protein-4 acts as an ovarian follicle survival factor and promotes p... 16934759 - Role of 5-lipoxygenase pathway in the regulation of raw 264.7 macrophage proliferation. 22551309 - Why dapsone stops seizures and may stop neutrophils' delivery of vegf to glioblastoma. 15528139 - Prospects for dendritic cell vaccination against fungal infections in hematopoietic tra... 6971199 - The association of patient-held records and completion of immunizations. 21970839 - Aiming at metabolic syndrome. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Head & neck Volume: 32 ISSN: 1097-0347 ISO Abbreviation: Head Neck Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-27 Completed Date: 2011-02-04 Revised Date: 2012-05-24 |
Medline Journal Info:
|
Nlm Unique ID: 8902541 Medline TA: Head Neck Country: United States |
Other Details:
|
Languages: eng Pagination: 1412-21 Citation Subset: IM |
Copyright Information:
|
© 2010 Wiley Periodicals, Inc. |
Affiliation:
|
Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
therapeutic use Antineoplastic Agents / therapeutic use* Carcinoma, Squamous Cell / drug therapy*, metabolism Cisplatin / therapeutic use Drug Resistance, Neoplasm Head and Neck Neoplasms / drug therapy*, metabolism Humans Protein Kinase Inhibitors / therapeutic use Quinazolines / therapeutic use Receptor, Epidermal Growth Factor / antagonists & inhibitors*, metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
P50 CA097190/CA/NCI NIH HHS; R01 CA077308/CA/NCI NIH HHS; R01 CA077308-12/CA/NCI NIH HHS; R01 CA077308-14/CA/NCI NIH HHS; R01 CA098372-08/CA/NCI NIH HHS; R01 CA77308/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Protein Kinase Inhibitors; 0/Quinazolines; 0/cetuximab; 0/erlotinib; 15663-27-1/Cisplatin; 184475-35-2/gefitinib; EC 2.7.10.1/Receptor, Epidermal Growth Factor |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inhibitors of hyaluronan export from hops prevent osteoarthritic reactions.
Next Document: Necrotizing fasciitis of the head and neck.